



Windlas Biotech Limited

Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199

Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030

CIN-L74899UR2001PLC033407

February 10, 2026

To
Listing / Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

To
Listing / Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

BSE CODE: 543329

NSE SYMBOL: WINDLAS

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received a Show Cause Notice from the Office of the Commissioner, Food Safety & Drug Administration (Uttarakhand) on February 9, 2026.

The authority has temporarily suspended the manufacturing of Codeine-containing cough syrup. The Company is in the process of submitting a detailed response to the Show Cause Notice within the stipulated timelines.

The affected product line contributed Rs. 55.21 crore to the Company's total revenue in current financial year till February 9, 2026. The impact is limited only to Codeine-based cough syrups, and the production of all other products continues as usual.

The Company remains committed to maintaining the highest quality and compliant manufacturing standards across all its facilities and to strengthening its compliance framework on an ongoing basis.

Kindly take the above on record.

Thanking you,

Yours faithfully,

For Windlas Biotech Limited

Ananta Narayan Panda
Company Secretary & Compliance Officer